Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Idorsia Pharmaceuticals Ltd. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners. The portfolio's active matters are spread across 2 distinct art units. KOSACK, JOSEPH R is the busiest examiner with 1 pending office action.
This distribution shows that each of the 4 pending office actions is being reviewed by a different individual. The involvement of 2 distinct art units suggests that the technologies are split between two specialized examination groups. Practitioners must coordinate across 4 distinct examiners to advance the 4 pending office actions currently in the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.2% |
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705346 | CCR6 RECEPTOR MODULATORS | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | ROMERO, KRISTEN WANG | 87d overdue |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | CHO, DAVID H | 9d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868772 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | KOSACK, JOSEPH R | — | §112 | Non-Final OA | — | Pending | Nov 24, 2024 |
| 18705346 | CCR6 RECEPTOR MODULATORS | BAUER, BRIANNA LEE | — | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | CHO, DAVID H | 1693 | DP | Final Rejection | 9d | Pending | Sep 01, 2023 |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | ROMERO, KRISTEN WANG | 1624 | §102§112DP | Non-Final OA | 87d overdue | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial